Charles River Laboratories vs Lonza: CDMO Comparison

Side-by-side comparison of Charles River Laboratories and Lonza on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score
92/100
Quality (FDA + GMP)
99/100
FDA inspections
8
— NAI / VAI / OAI
5 / 3 / 0
FDA warning letters
0
EMA GMP certificates (active)
9
MHRA GMP certificates (compliant)
2
Clinical programs (matched)
0
Capacity
Limited
Modalities
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Lonza → 78.2
Basel, Switzerland
Signal Score
78/100
Quality (FDA + GMP)
95/100
FDA inspections
2
— NAI / VAI / OAI
0 / 2 / 0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
5
Clinical programs (matched)
1
Capacity
Modalities
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein

Key differences

  • Charles River Laboratories has more FDA inspections on record (8 vs 2) — a deeper regulatory paper trail.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Charles River Laboratories has materially broader EMA GMP coverage (9 active certificates vs 3) — stronger EU footprint.
  • Lonza has stronger MHRA / UK coverage (5 compliant certificates vs 2).
  • Composite Signal Score: Charles River Laboratories 92/100 vs Lonza 78/100 — a 14-point gap reflecting the combined quality, capacity and financial signal.

On a 13-modality CDMO landscape, both Charles River Laboratories and Lonza qualify as AAV manufacturers; Charles River Laboratories carries the higher composite Signal Score for AAV programs in this comparison.

What to evaluate for AAV programs

Both Charles River Laboratories and Lonza qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

Platform & scale

Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.

Capsid quality

Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.

Regulatory readiness

For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.

Capacity & timelines

AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.

See all AAV CDMOs ranked by Signal Score →

Frequently asked: Charles River Laboratories vs Lonza

Which has the stronger FDA inspection record, Charles River Laboratories or Lonza?

Both Charles River Laboratories and Lonza maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Charles River Laboratories has 8 FDA inspections on record; Lonza has 2.

How do Charles River Laboratories and Lonza compare on European GMP coverage?

Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Lonza holds 3 active EMA GMP certificates and 5 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Charles River Laboratories or Lonza?

Charles River Laboratories is matched to 0 ClinicalTrials.gov records as a manufacturing partner; Lonza is matched to 1. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for AAV manufacturing — Charles River Laboratories or Lonza?

Both Charles River Laboratories and Lonza are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Charles River Laboratories carries a Signal Score of 92/100 and Lonza carries 78/100 — a meaningful lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Charles River Laboratories and Lonza for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.